RT Journal Article
SR Electronic
T1 Whole genome analysis of plasma fibrinogen reveals population-differentiated genetic regulators with putative liver roles
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.07.23291095
DO 10.1101/2023.06.07.23291095
A1 Huffman, Jennifer E
A1 Nicolas, Jayna
A1 Hahn, Julie
A1 Heath, Adam S
A1 Raffield, Laura M
A1 Yanek, Lisa R
A1 Brody, Jennifer A
A1 Thibord, Florian
A1 Almasy, Laura
A1 Bartz, Traci M
A1 Bielak, Lawrence F.
A1 Bowler, Russell P
A1 Carrasquilla, Germán D
A1 Chasman, Daniel I
A1 Chen, Ming-Huei
A1 Emmert, David B
A1 Ghanbari, Mohsen
A1 Haessle, Jeffery
A1 Hottenga, Jouke-Jan
A1 Kleber, Marcus E
A1 Le, Ngoc-Quynh
A1 Lee, Jiwon
A1 Lewis, Joshua P
A1 Li-Gao, Ruifang
A1 Luan, Jian’an
A1 Malmberg, Anni
A1 Mangino, Massimo
A1 Marioni, Riccardo E
A1 Martinez-Perez, Angel
A1 Pankratz, Nathan
A1 Polasek, Ozren
A1 Richmond, Anne
A1 Rodriguez, Benjamin AT
A1 Rotter, Jerome I
A1 Steri, Maristella
A1 Suchon, Pierre
A1 Trompet, Stella
A1 Weiss, Stefan
A1 Zare, Marjan
A1 Auer, Paul
A1 Cho, Michael H
A1 Christofidou, Paraskevi
A1 Davies, Gail
A1 de Geus, Eco
A1 Deleuze, Jean-François
A1 Delgado, Graciela E
A1 Ekunwe, Lynette
A1 Faraday, Nauder
A1 Gögele, Martin
A1 Greinacher, Andreas
A1 He, Gao
A1 Howard, Tom
A1 Joshi, Peter K
A1 Kilpeläinen, Tuomas O
A1 Lahti, Jari
A1 Linneberg, Allan
A1 Naitza, Silvia
A1 Noordam, Raymond
A1 Paüls-Vergés, Ferran
A1 Rich, Stephen S
A1 Rosendaal, Frits R
A1 Rudan, Igor
A1 Ryan, Kathleen A
A1 Souto, Juan Carlos
A1 van Rooij, Frank JA
A1 Wang, Heming
A1 Zhao, Wei
A1 Becker, Lewis C
A1 Beswick, Andrew
A1 Brown, Michael R
A1 Cade, Brian E
A1 Campbell, Harry
A1 Cho, Kelly
A1 Crapo, James D
A1 Curran, Joanne E
A1 de Maat, Moniek PM
A1 Doyle, Margaret
A1 Elliott, Paul
A1 Floyd, James S
A1 Fuchsberger, Christian
A1 Grarup, Niels
A1 Guo, Xiuqing
A1 Harris, Sarah E
A1 Hou, Lifang
A1 Kolcic, Ivana
A1 Kooperberg, Charles
A1 Menni, Cristina
A1 Nauck, Matthias
A1 O’Connell, Jeffrey R
A1 Orrù, Valeria
A1 Psaty, Bruce M
A1 Räikkönen, Katri
A1 Smith, Jennifer A
A1 Soria, Jose Manuel
A1 Stott, David J
A1 van Hylckama Vlieg, Astrid
A1 Watkins, Hugh
A1 Willemsen, Gonneke
A1 Wilson, Peter
A1 Ben-Shlomo, Yoav
A1 Blangero, John
A1 Boomsma, Dorret
A1 Cox, Simon R
A1 Dehghan, Abbas
A1 Eriksson, Johan G
A1 Fiorillo, Edoardo
A1 Fornage, Myriam
A1 Hansen, Torben
A1 Hayward, Caroline
A1 Ikram, M. Arfan
A1 Jukema, J Wouter
A1 Kardia, Sharon LR
A1 Lange, Leslie A
A1 März, Winfried
A1 Mathias, Rasika A
A1 Mitchell, Braxton D
A1 Mook-Kanamori, Dennis O
A1 Morange, Pierre-Emmanuel
A1 Pedersen, Oluf
A1 Pramstaller, Peter P
A1 Redline, Susan
A1 Reiner, Alexander
A1 Ridker, Paul M
A1 Silverman, Edwin K
A1 Spector, Tim D
A1 Völker, Uwe
A1 Wareham, Nick
A1 Wilson, James F
A1 Yao, Jie
A1 VA Million Veteran Program
A1 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium
A1 Trégouët, David-Alexandre
A1 Johnson, Andrew D
A1 Wolberg, Alisa S
A1 de Vries, Paul S
A1 Sabater-Lleal, Maria
A1 Morrison, Alanna C
A1 Smith, Nicholas L
YR 2023
UL http://medrxiv.org/content/early/2023/06/12/2023.06.07.23291095.abstract
AB Genetic studies have identified numerous regions associated with plasma fibrinogen levels in Europeans, yet missing heritability and limited inclusion of non-Europeans necessitates further studies with improved power and sensitivity. Compared with array-based genotyping, whole genome sequencing (WGS) data provides better coverage of the genome and better representation of non-European variants. To better understand the genetic landscape regulating plasma fibrinogen levels, we meta-analyzed WGS data from the NHLBI’s Trans-Omics for Precision Medicine (TOPMed) program (n=32,572), with array-based genotype data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (n=131,340) imputed to the TOPMed or Haplotype Reference Consortium panel. We identified 18 loci that have not been identified in prior genetic studies of fibrinogen. Of these, four are driven by common variants of small effect with reported MAF at least 10% higher in African populations. Three (SERPINA1, ZFP36L2, and TLR10) signals contain predicted deleterious missense variants. Two loci, SOCS3 and HPN, each harbor two conditionally distinct, non-coding variants. The gene region encoding the protein chain subunits (FGG;FGB;FGA), contains 7 distinct signals, including one novel signal driven by rs28577061, a variant common (MAF=0.180) in African reference panels but extremely rare (MAF=0.008) in Europeans. Through phenome-wide association studies in the VA Million Veteran Program, we found associations between fibrinogen polygenic risk scores and thrombotic and inflammatory disease phenotypes, including an association with gout. Our findings demonstrate the utility of WGS to augment genetic discovery in diverse populations and offer new insights for putative mechanisms of fibrinogen regulation.Key PointsLargest and most diverse genetic study of plasma fibrinogen identifies 54 regions (18 novel), housing 69 conditionally distinct variants (20 novel).Sufficient power achieved to identify signal driven by African population variant. Links to (1) liver enzyme, blood cell and lipid genetic signals, (2) liver regulatory elements, and (3) thrombotic and inflammatory disease.Competing Interest StatementLaura Raffield is a consultant for the TOPMed Administrative Coordinating Center (through WeStat). Ruifang Li-Gao is a part-time consultant for Metabolon, Inc. Michael Cho has received grant support from Bayer. Bruce Psaty serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson and Johnson. In the past three years, Edwin K. Silverman has received grant support from Bayer.Funding StatementMolecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). See the TOPMed Omics Support Table in the Supplemental Data for study specific omics support information. Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.CHARGE is supported by R01HL-105756 and the CHARGE and TOPMed Hemostasis Working Groups by R01HL-134894, R01HL-139553, and R01HL-141291.This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award I01-BX004821.The study was supported by the Novo Nordisk Foundation (grant number NNF18CC0034900). D-A.T was supported by the EPIDEMIOM-VT Senior Chair of Excellence from the University of Bordeaux initiative of Excellence (IdEX). Additional study-specific funding and acknowledgements can be found in the Supplemental Data.The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.This publication does not represent the views of the Department of Veteran Affairs, the US National Institutes of Health, the National Heart, Lung and Blood Institute, the US Department of Health and Human Service, or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMeta-analysis summary statistics will be available through the CHARGE dbGaP accession (phs000930) or upon request to the corresponding author. Individual-level data for TOPMed studies is available through their relevant dbGaP accessions as listed in the TOPMed Omics Support Table in the Supplemental Data.